Drug discovery

Eli Lilly has acquired rights to Insilico Medicine’s AI-discovered drug pipeline in a $2.75 billion deal. This significant partnership highlights AI’s growing role in drug discovery. The agreement includes an upfront payment and future royalties, reflecting the innovative nature of the collaboration. Insilico, a leader in AI-driven drug discovery, has numerous candidates in clinical trials. This deal leverages Lilly’s expertise with Insilico’s AI platform, aiming to accelerate the development of new therapies and reinforce Lilly’s expansion into the Chinese market.

Harbour BioMed has increased its ownership in Spruce Biosciences to approximately 3.8%, marking a deeper strategic alliance beyond a traditional licensing agreement. This move underscores Harbour BioMed’s confidence in Spruce’s SPR202 antibody therapy and their collaborative efforts to accelerate novel antibody treatments for conditions like congenital adrenal hyperplasia. The expanded partnership signifies a shared commitment to bringing innovative therapies to patients.

Renovaro Inc. (NASDAQ:RENB) rebranded as Lunai Bioworks, focusing on AI-powered biodefense, drug discovery, and advanced diagnostics. This follows its merger with BioSymetrics, bringing partnerships with Janssen, Pfizer, Merck, and others. Lunai’s platform uses multimodal AI for real-time biological signal analysis, enabling early detection, patient stratification, and therapeutic targeting. The stock will continue trading under the RENB ticker. CEO David Weinstein emphasizes the company’s commitment to addressing global health and security challenges with AI-driven solutions.